As Founder of InFocus Therapeutics, Emily Fang is responsible for defining the company’s vision, strategy, and global execution, building a cross-border AI drug discovery platform that integrates scientific rigor with international business development and capital formation. She drives corporate strategy across scientific priorities, partnerships, and financing, ensuring that InFocus advances high-value programs while forging strategic alliances across the US, Europe, and Asia.

‍

Emily has more than twelve years of experience in integrated drug discovery and development across oncology, neuroscience, immunology, and genetic diseases, spanning early biotechnology startups to multinational organizations. She has operated at the intersection of science, strategy, and commercialization throughout her career, bridging early discovery technologies into strategic partnerships and commercial opportunities. Before founding InFocus, she served as Deputy Head of Business Development at Oncodesign, a French biotech and contract research organization, where she led international strategic partnerships with major biopharma companies and research organizations.

‍

Emily specializes in global business development and strategic partnerships and has negotiated and closed multi-million-dollar, multi-year collaborations with biotechnology and pharmaceutical companies across the United States, Canada, Japan, France, Belgium, Germany, and Switzerland. Her experience spans scientific partnering, technology evaluation, deal structuring, and alliance management, giving her a differentiated understanding of how scientific programs translate into value for industry partners and investors. She has also held director-level roles in established global organizations, where she built and managed high-impact business development functions and strategic initiatives.

‍

In addition to her role at InFocus, Emily serves as a Board Member at GenSensor, a French deeptech biotechnology company focused on bioproduction, advising on strategy, partnerships, and international growth. Her career reflects a consistent focus on enabling next-generation biotechnologies to scale globally through rigorous scientific execution and cross-border strategic alignment.

‍

Emily received her scientific training in medicinal chemistry, molecular biology, and stem cell biology through the Wellcome Trust PhD Programme at the University of Dundee. She later pursued MBA studies at Imperial College Business School, complementing her scientific background with business and strategic training.

‍

As Chief Scientific Officer of InFocus Therapeutics, Dr. Kyle Giesler is responsible for shaping the company’s scientific strategy, guiding the development and integration of medicinal chemistry and data-driven discovery across high-value preclinical programs. He defines the scientific rigor behind compound progression from hit identification through lead optimization and candidate selection, ensuring that mechanistically sound and data-informed decisions accelerate the advancement of the pipeline.

‍

Kyle is an innovative drug hunter with experience across oncology, inflammation, CNS, and virology, with a strong track record in early discovery and medicinal chemistry leadership. He has spent the last several years at biotechnology startups, including Aduro Biotech (merged with Chinook Therapeutics in 2020 and acquired by Novartis in 2023) and Atomwise, where he led medicinal chemistry programs advancing compounds from hit-to-lead through lead optimization and toward development candidate selection.

‍

Kyle’s scientific contributions span computational design, synthetic medicinal chemistry, and early discovery strategy. He holds two U.S. patents and has authored more than twenty publications, including work conducted as part of the United States Department of Defense and in the academic literature. Notably, one of his publications was distributed within the DoD as part of the U.S. government’s response to the COVID-19 pandemic.

‍

His multidisciplinary perspective and experience navigating early-stage biotech environments enable him to connect chemical design, data interpretation, and program decision-making in fast-moving discovery settings, , with an emphasis on identifying levers of asset differentiation early in the design process.

‍

Kyle earned his Ph.D. in Chemistry from Emory University, completed postdoctoral research at the University of California, Berkeley, and holds a Bachelor’s degree in Chemistry from the University of Central Florida.

As Chief Technical Officer of InFocus Therapeutics, Dr. Dirk Tomandl is responsible for defining and executing the company’s technological vision, shaping its computational and AI strategy, and ensuring that cutting-edge data-driven approaches accelerate its drug discovery efforts. He oversees platform architecture, drives the integration of AI, advanced analytics, cheminformatics, and computational chemistry. He is developing proprietary AI technology and computational tools that power InFocus' drug discovery programs.

‍

Dirk has over 25 years of experience working in drug discovery and cheminformatics. He balances visionary leadership with practical, hands-on scientific expertise, demonstrated at roles at Atomwise, Corteva Agriscience, Dow AgroSciences, Eli Lilly, Graffinity Pharmaceuticals, and Merck KGaA. His tenure at Atomwise was marked by leading a cheminformatics team dedicated to ligand-based methods such as ADMET and pKi models, generative de-novo design, and innovating and automating the lead generation and optimization processes.

‍

At Corteva (formerly Dow AgroSciences), he built a cheminformatics team from scratch and established cheminformatics as a foundation for agrochemical research. He pioneered cheminformatics both as a science and as practical tools and models that impacted the entire crop protection research organization. At Eli Lilly, he developed numerous cheminformatics tools and supported dozens of drug discovery projects. Dirk’s ability to drive cross-functional team leadership and stakeholder alignment coupled with creative problem-solving has accelerated the pace of discovery and optimization in drug and agrochemical research organizations. It has been rewarded with numerous internal awards.

‍

Dirk is passionate about drug discovery and agrochemical research because they serve a purpose. They are also great fun because of the complex problems to be solved along its way. What keeps Dirk up at night is to innovate the Design-Make-Test-Analyze (DMTA) cycle in order to create new chemicals faster and better. Transforming organizations from data-generation to decision-making is key. Data-driven approaches, artificial intelligence, in-silico methods, and advanced analytics improve the quality of decisions and reduce the number of DMTA cycles. This leads to better molecules faster. Molecules that solve unmet medical and agriculture needs.

‍

Dirk holds a Ph.D. in Cheminformatics, Physics, Theoretical Chemistry, and Machine Learning from the University of Vienna (Austria) and the Institute of Molecular Biotechnology e.V. in Jena (Germany). Dirk has a Masters in Physics, Biophysics from the University of Erlangen-Nuremberg, Germany.

As Chief Discovery Officer of InFocus Therapeutics, Dr. Jérémy Besnard is responsible for shaping the company’s drug discovery and design strategy, guiding the scientific logic behind its high-value small-molecule programs, and ensuring that design-driven decisions accelerate pipeline advancement.

‍

He oversees the development of core design principles across programs, ensures that data-informed and mechanism-grounded reasoning directs molecular progression, and brings deep medicinal chemistry expertise to drive high-quality candidate generation.

‍

Jérémy plays a pivotal role at key inflection points, co-interpreting data with chemistry and biology leads, challenging assumptions, and steering teams toward the most impactful and highest-probability experiments. He contributes a high-leverage strategic perspective, collaborates with computational teams to transform exploratory analyses into reusable tools, and strengthens InFocus’ overall scientific rigor and technical differentiation.

‍

Jérémy is a co-inventor of the original Exscientia technology for the Automated Design of Ligands to Polypharmacological Profiles, which was developed during his PhD and published in Nature. Jérémy graduated with a French Diplôme d’Ingénieur Chimiste from Ecole Nationale Superieure de Chimie de Montpellier and gained a MSc in Chemical Biology from the University of Montpellier II in 2008.

‍

As Chief Designer at Exscientia, Jérémy delivered four clinical candidate molecules for psychiatric disorders and oncology, additionally contributing to IND-ready projects in various indications.

‍

He is the winner of the 10th Capps Green Zomaya Award for Medicinal or Computational Chemistry in 2022, following his RSC Rising Star in Industry Award in 2017. The Award acknowledges Jérémy’s work at the University of Dundee, UK and Exscientia, UK in the development of AI technology and its application to the design of novel drugs. In particular, this technology has been used in the identification of 5HT1a agonists, which went into clinical evaluation for the treatment of obsessive-compulsive disorder (OCD).

As Chief R&D Officer of InFocus Therapeutics, Dr. Jean-François Mirjolet is responsible for leading the company’s nonclinical research and development strategy, spanning in vitro biology, in vivo pharmacology, translational science, and IND-enabling planning. He defines the biological and translational direction of programs, ensuring that mechanistically relevant models and clinically informed study designs accelerate the path from in vivo proof-of-concept to IND.

‍

Jean-François is a senior scientific executive with more than twenty years of experience in preclinical drug discovery and translational research, spanning oncology, immuno-oncology, fibrosis, and inflammatory diseases. He has held leadership roles in both pharmaceutical and CRO environments, with responsibility for building and directing large, multidisciplinary teams across in vitro biology, pharmacology, medicinal and analytical chemistry, and DMPK/bioanalysis.

‍

Throughout his career, Jean-François has demonstrated strong strategic and operational leadership, overseeing complex preclinical portfolios from target validation through in vivo proof of concept. He has a proven ability to align scientific innovation with business objectives, ensuring rigorous execution, budgetary control, and regulatory compliance, including GMO and biosafety frameworks.

‍

Jean-François brings deep expertise in advanced screening technologies and translational models, and has contributed directly to intellectual property generation, including multiple oncology-focused patents. In parallel, he has supported business development through scientific strategy, proposal development, and senior-level client engagement.

‍

Overall, Jean-François combines scientific depth, organizational leadership, and strategic vision, with a consistent track record of advancing high-quality preclinical programs and building high-performing teams in demanding R&D environments.

‍

Jean-François holds a Ph.D. in Pharmacology from Poincaré University of Nancy (France) and a Master’s in Metabolism and Mechanism of Action of Drugs from Poincaré University of Nancy (France).

As Chief Financial Officer and Head of Corporate Development at InFocus Therapeutics, Johnny Yu brings extensive experience across corporate development, M&A, venture investing, and ecosystem building in biotech and healthcare. He is responsible for financial strategy, corporate structuring, investor relations, and cross-border venture engagement, ensuring that InFocus scales with strong capitalization, governance, and strategic industry alignment.

‍

Johnny currently serves as Managing Partner at Mosaic Venture Lab and the FSP-Mosaic Innovation & Sustainability Fund. He previously led corporate development and M&A functions at multinational and domestic pharmaceutical companies, where he gained extensive experience integrating upstream and downstream segments of the healthcare value chain and building complete supply chains across therapeutic, manufacturing, and commercial domains.

‍

He later joined Yuanta Asia Investment and collaborated with sovereign wealth funds including Korea’s KDB and Singapore’s GIC, engaging deeply in the development of biotech and healthcare innovation ecosystems across Asia, Europe, and the United States.

‍

Over his career, Johnny has driven strategic investments, product licensing, and vertical integration initiatives, frequently serving as lead investor or board member for biotechnology startups and advising CEOs on financing, partnerships, and company-building. His ecosystem-building work culminated in the co-founding of Mosaic Venture Lab in 2022, alongside Volker Heistermann and Ken Huang, and the subsequent launch of an early-stage innovation fund with FSP Group.

‍

Recognizing the rapid emergence of cell and gene therapy, Mosaic co-founded CellTech Innovation Venture Studio in 2023, an accelerator focused on advanced therapies; to date, it has supported more than 30 startups across Europe, the United States, Japan, and Taiwan.

‍

Johnny holds a Bachelor’s degree in Pharmacy from Taipei Medical University and earned his MBA from the University of Birmingham Business School (UK). He brings a unique cross-border perspective spanning Asia, Europe, and the US, connecting biopharma strategy, investment capital, and healthcare innovation to accelerate company growth and ecosystem development.

As Chief Operating Officer at InFocus Therapeutics, Christa Sempertegui leads strategic communications, ecosystem coordination, and operational alignment across the organization. She drives the company’s external positioning and visibility within the biotech and techbio ecosystem, and supports coordinated engagement within key networks and associations.

‍

Christa brings experience in business operations, organizational strategy, and performance management in the biotech sector. Previously, she served as Manager of Business Operations and Development at Oncodesign, a French biotech and contract research organization, where she contributed to long-term growth through the expansion of commercial activities, strategic collaborations, and the implementation of critical supporting infrastructure. She also played a central role in establishing KPIs, business intelligence tools, data monitoring, and performance analysis systems to support organizational growth.

‍

At InFocus, Christa is specializing in non-dilutive funding strategy and public financing mechanisms, acting as a reference point for grants and innovation funding instruments that complement venture-backed growth. She coordinates the company’s engagement with innovation networks, associations, and ecosystem partners, helping to build institutional linkages necessary for long-term success.

‍

Christa holds a Master’s degree in Business Administration from the School of Management at the University of Caen in France.

Mylène Fanchon is Director of R&D Operations at InFocus Therapeutics, where she supports the planning, coordination, and execution of integrated preclinical discovery programs. She works across functions to operationalize in vitro and in vivo studies, align scientific objectives with program timelines and quality standards, and ensure smooth coordination with external research partners and CROs.

‍

Mylène brings ten years of experience in oncology-focused preclinical research within CRO environments, with a strong foundation in project management, study logistics, and client-facing coordination. At Charles River Laboratories, she managed in vivo oncology studies for pharmaceutical clients and later moved into a product specialist role supporting project scoping and operational execution. Prior to Charles River, she worked as a Preclinical Study Coordinator at Oncodesign, where she supported study planning, client communication, and project logistics.

‍

Her scientific background includes research roles at Institut Curie and INSERM, where she contributed to oncology and hematopoiesis research in academic settings. Across her roles, she has developed a practical understanding of how preclinical discovery programs operate end-to-end—from study scoping and resource allocation to data delivery and stakeholder communication—supporting efficient and reliable execution in fast-moving R&D environments.

‍

Mylène holds an M.Sc. in Biology and Health with a specialization in Oncology from Université Paris-Saclay and ENS Cachan, and a B.Sc. in Biology with a specialization in Biochemistry and Molecular Biology from Université de Bourgogne.

Dr Nicolas Martin is a biopharma leader with over a decade of international experience driving innovation across immunology, oncology, diagnostics and digital health. He has held multiple leadership positions across several international pharmaceutical companies.

‍

Nicolas has successfully launched specialty care medicines and precision health solutions in Asia-Pacific as well as global markets. His expertise bridges science, medicine, and business strategy, with a focus on integrating digital transformation into healthcare to improve patient outcomes.

‍

Nicolas holds a PhD in Genetic Epidemiology from the University of Queensland, an MBA from Macquarie Graduate School of Management, and degrees in Life Sciences and Biochemistry from the University of Edinburgh and the Université de Bourgogne. He brings a combination of scientific depth and strategic acumen to advance innovation in the biotech ecosystem.

Dr. Namita Chatterjee is a discovery biologist specializing in RNA-targeted therapeutics, target validation, and early-stage mechanism-of-action studies. She brings industry experience in small-molecule RNA modulation and extensive training in molecular oncology, biomarker strategy, and translational model systems.

‍

Dr. Chatterjee previously worked in Discovery Biology at PTC Therapeutics, contributing to early discovery programs focused on modulating mRNA splicing and RNA regulation for oncology applications. In this capacity, she supported target hypothesis generation, assay development, screening and optimization workflows, biomarker identification, and mechanistic studies using RNAseq and biochemical profiling.

‍

She collaborated closely with chemistry, bioinformatics, and pharmacology functions to refine target hypotheses and advance data-driven decision-making in discovery-stage research.

‍

Before joining PTC, Dr. Chatterjee completed a postdoctoral fellowship at the Knight Cancer Institute at Oregon Health & Science University (OHSU), where she investigated microRNA biology, endothelial stress pathways, and immuno-oncology mechanisms.

‍

Her academic training includes a PhD in Biomedical Sciences from the State University of New York at Albany, an MS in Biochemistry from the University of Notre Dame, and additional research training at Technische Universität Dresden.

‍

With a multidisciplinary background spanning molecular oncology, RNA biology, and discovery-stage drug development, Dr. Chatterjee combines scientific depth with cross-functional experience in translational assay design and data-driven target validation. She brings valuable expertise to InFocus’s RNA-targeted discovery efforts.